This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Robertson JIS . A critique of hypertension treatment trials and their evaluation. J Eval Clin Pract 2001; 7: 149–164.
Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000; 355: 1955–1964.
Dahlof B et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003.
Lithell H et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–886.
Wing LMH et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583–592.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997.
Lindholm LH et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoints reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 1004–1010.
Kjeldsen SE et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losartan Intervention For Endpoint Reduction (LIFE) substudy. JAMA 2002; 288: 1491–1498.
Devereux RB et al. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann Intern Med 2003; 139: 169–177.
Okin PM et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol. The Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study. Circulation 2003; 108: 684–690.
Blacher J et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000; 160: 1085–1089.
Wilkinson IB, Webb Christison DJ, Cockcroft JR . Isolated systolic hypertension: a radical rethink. BMJ 2000; 320: 1685.
Khattar RS et al. Effect of aging on the prognostic significance of ambulatory systolic, diastolic, and pulse pressure in essential hypertension. Circulation 2001; 104: 783–789.
Verdecchia P et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001; 104: 2039–2044.
Di Tullio MR et al. Left ventricular mass and geometry and the risk of ischemic stroke. Stroke 2003; 34: 2380–2386.
Selvetella G et al. Left ventricular hypertrophy is associated with asymptomatic cerebral damage in hypertensive patients. Stroke 2003; 34: 1766–1770.
Camargo MJF et al. Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. J Hypertens 1993; 11: 31–40.
Fornes P et al. Losartan's protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal. J Cardiovasc Pharmacol 1993; 22: 305–313.
Stier CT Jr, Adler LA, Levine S, Chander PN . Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats. J Hypertens 1993; 11 (Suppl 3): S37–S42.
Vacher E, Richer C, Giudicelli J-F . Effects of losartan on cerebral arteries in stroke-prone spontaneously hypertensive rats. J Hypertens 1996; 14: 1341–1348.
Nishimura Y, Ito T, Saavedra JM . Angiotensin II AT–1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 2000; 31: 2478–2486.
Schiffrin EL, Park JB, Intengan HD, Touyz RM . Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653–1659.
Klemsdal TO, Moan A, Kjeldsen SE . Effects of selective angiotensin II type 1 receptor blockade with losartan on arterial compliance in patients with mild essential hypertension. Blood Press 1999; 8: 214–219.
O’Rourke MF . From theory to practice: arterial haemodynamics in clinical hypertension. J Hypertens 2002; 20: 1901–1915.
Asmar RG, London GM, O’Rourke ME, Safar ME . Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient. A comparison with atenolol. Hypertension 2001; 38: 922–926.
Dart AM, Reid CM, McGrath B . Effects of ACE inhibitor therapy on derived central arterial wave forms in hypertension. Am J Hypertens 2002; 15: 477.
Monton M et al. Comparative effects of angiotensin II AT-1-receptor antagonists in vitro on human platelet activation. J Cardiovasc Pharmacol 2000; 35: 906–913.
Krämer C et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002; 90: 770–776.
Wurzner G et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001; 19: 1855–1860.
Mazzali M et al. Hyperuricemia induces a primary renal arteriopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002; 282: F991–F997.
Watanabe S et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40: 355–360.
Johnson RJ et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183–1190.
Weir CJ, Muir SW, Walters MR, Lees KR . Serum urate as an independent predictor of poor outcome and future vascular events after stroke. Stroke 2003; 34: 1951–1957.
Messerli FH, Beevers DG, Franklin SS, Pickering TG . B-blockers in hypertension—the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension. Am J Hypertens 2003; 16: 870–873.
Sleight P, Yusuf S . New evidence on the importance of the renin–angiotensin system in the treatment of high-risk patients with hypertension. J Hypertens 2003; 21: 1599–1608.
Hansson L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999; 353: 611–616.
The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–153.
Boden G, Hoeldtke RD . Nerves, fat, and insulin resistance. N Engl J Med 2003; 349: 1966–1967.
Wang C-H et al. Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats. Circulation 2003; 107: 1923–1929.
Engeli S et al. The adipose-tissue renin–angiotensin system: role in the metabolic syndrome? Int J Biochem Cell Biol 2003; 35: 807–825.
Leung PS, Chappell MC . A local pancreatic renin–angiotensin system: endocrine and exocrine roles. Int J Biochem Cell Biol 2003; 35: 838–846.
Grassi G et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21: 1761–1769.
Lindholm LH et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21: 1563–1574.
Dunder K et al. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. BMJ 2003; 326: 681–685.
Lindholm LH et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879–1886.
Wong SYS, McInnes GT, MacDonald TM . Why not prescribe the best drugs for hypertension now? J Hum Hypertens 2003; 17: 505–511.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nicholls, M. LIFE and SCOPE: what guidance do they offer alongside ALLHAT and ANBP2?. J Hum Hypertens 18, 295–300 (2004). https://doi.org/10.1038/sj.jhh.1001675
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1001675